Uniquely Suitable GvHD models.

Studies show that acute Graft versus Host Disease (aGvHD) can occur in up to 50% of patients that are recipients of stem cell transplantation (HCT) from an HLA-matched sibling. This number goes even higher in unmatched donors. The incidence of chronic Graft versus Host Disease (cGvHD) ranges somewhere between 6% to 80%. More than 10% of patients suffering from GvHD will not survive its complications.

Hematopoietic stem cell transplantations (HSCTs) have been shown to be the cure to numerous blood and bone marrow cancers. The catch? GvHD is one of the most common complications in HSCTs. At PharmaLegacy, our end-goal is not the choice of a proper study model, or the meticulous compilation of data. Our end-goal is the same as yours: serving patients in need of better treatments.

Contact Us
Graft-Versus-Host Disease


Committed to quality:

  • 120,000 square feet of vivarium space
  • Completed over 400 FDA / CFDA IND filings
  • Operations and IT structured for maximum protection of client’s data and IP
  • Electronically managed, traceable research data

If it’s precision-tailored solutions for your pipelines that you are looking for, PharmaLegacy has the answer. Contact us now.

Contact Us

Can you trust your animal model to provide you with the correct answers?

No animal study can predict with complete certainty how a therapy will perform in human subjects, but it is PharmaLegacy’s job to ensure that you come as close to certainty as possible. Download our brochure on non-human primate (NHP) models and see how PharmaLegacy ensures that your studies utilize the most physiologically relevant models.


    We’re ready when you are.

    Tell us your pharmacology challenges.